Skip to content

Fertility

What Is IVF Really Like? 10 Truths About Success Rates, Cost and the Two-Week Wait

IVF is an assisted reproductive procedure where eggs are fertilised in a lab. Learn how it works, success rates by age, and UK cycle costs.
Couple reviewing a treatment plan on a tablet with a female doctor in a bright clinic office

Quick Answer: In vitro fertilisation (IVF) is an assisted reproductive procedure where clinicians retrieve eggs, fertilise them with sperm in a laboratory, and culture them into embryos before uterine transfer. Real-world success, physical discomfort, and out-of-pocket expenses vary significantly based on patient age, diagnosis, and treatment protocols.

Key Takeaways:

  • UK live birth rates per embryo transfer range from roughly 33% for women under 35 to below 5% for women aged 43 and older.
  • Anti-Müllerian hormone (AMH) tests evaluate ovarian egg reserve, but they do not predict egg quality or ensure conception.
  • Elective single embryo transfer (eSET) is the standard UK clinical practice to minimise serious maternal and neonatal health risks.
  • A single private IVF cycle typically costs between £6,000 and £10,000 once medication, laboratory add-ons, and embryo freezing are included.
  • Embryo implantation failure is most commonly driven by invisible chromosomal abnormalities rather than everyday physical activities during the two-week wait.

In vitro fertilisation is an assisted reproductive technology used to treat infertility, severe male factor subfertility, and genetic conditions. During treatment, specialist clinicians use hormonal medication to stimulate the ovaries, collect mature eggs via transvaginal aspiration, fertilise them with sperm in an embryology laboratory, and culture the developing embryos. One or more embryos are subsequently placed into the patient's uterus with the aim of achieving a viable, full-term clinical pregnancy.

What is IVF and how does the treatment actually work?

In vitro fertilisation (IVF) is an assisted reproductive procedure where clinicians surgically retrieve eggs from the ovaries, fertilise them with sperm in a laboratory, and culture them into embryos before transferring one into the uterus. A complete cycle lasts between four and seven weeks, spanning ovarian suppression, daily hormone stimulation, monitoring scans, egg retrieval, laboratory fertilisation, and embryo transfer.

Understanding how does IVF work requires looking past clinic brochures to the biological sequence of the cycle. A standard treatment round bypasses natural single-follicle ovulation to mature multiple oocytes simultaneously. Clinicians tailor the dosage of follicle-stimulating hormone (FSH) and luteinising hormone (LH) according to individual diagnostic profiles, balancing the goal of obtaining 8 to 15 mature eggs against the medical risk of hyperstimulation.

The overall medical pathway follows a strict chronological progression:

  1. Initial assessment and suppression: Blood tests, ultrasound scans, and semen analyses establish baseline health, followed in some long-protocol cycles by GnRH agonists to pause the natural menstrual cycle.
  2. Controlled ovarian stimulation: The patient administers subcutaneous hormone injections daily for 10 to 14 days to recruit and grow multiple ovarian follicles.
  3. Ultrasound and hormonal monitoring: Transvaginal scans and serum oestradiol tests are conducted every two to three days to evaluate follicular size and uterine lining thickness.
  4. Final maturation trigger: Once leading follicles reach 17 to 20 millimetres, the patient takes a precise hormonal injection of human chorionic gonadotropin (hCG) or a GnRH agonist to prompt final oocyte maturation.
  5. Transvaginal oocyte retrieval: Approximately 35 to 36 hours after the trigger, the specialist retrieves follicular fluid containing eggs using ultrasound-guided needle aspiration under conscious sedation or general anaesthesia.
  6. Laboratory fertilisation: Embryologists isolate the eggs and combine them with prepared sperm using either standard insemination or intracytoplasmic sperm injection (ICSI).
  7. Embryo culture: Fertilised zygotes develop in specialised incubators over three to five days until they reach the blastocyst stage.
  8. Embryo transfer: A doctor passes a thin, flexible catheter through the cervix under transabdominal ultrasound guidance to deposit one selected embryo into the uterine cavity.
  9. Luteal support: The patient takes daily progesterone via vaginal pessaries, gels, or injections to prepare and maintain the endometrium for implantation.
  10. The pregnancy test: A quantitative serum beta-hCG blood test or sensitive urine test confirms whether implantation has occurred, taken roughly 14 days post-retrieval.

Truths 1 to 3: AMH levels, daily hormone injections, and egg retrieval

Anti-Müllerian hormone (AMH) measures ovarian reserve and predicts how many eggs can be stimulated, but it does not indicate egg quality or natural fertility. Daily hormone injections typically cause mild site bruising, abdominal bloating, and mood fluctuations rather than severe pain, while egg collection is performed under conscious sedation or general anaesthesia, leaving most patients with period-like cramping for 24 to 48 hours.

These initial phases represent the first hurdle for patients, mixing biological realities with day-to-day physical management.

Truth 1: AMH predicts quantity, not chromosomal quality

Anti-Müllerian hormone is produced by the granulosa cells of small, growing follicles within the ovaries. A blood test measures this value in picomoles per litre (pmol/L) or nanograms per millilitre (ng/mL). A high AMH indicates a robust ovarian reserve, meaning a clinic can reasonably expect a high yield of retrievable eggs. A low AMH indicates a reduced reserve, often leading to fewer collectable oocytes.

However, AMH reveals nothing about the chromosomal normality or developmental potential of those eggs. A 28-year-old with a low AMH of 4.5 pmol/L will produce fewer eggs during stimulation, yet a high proportion of those eggs will remain genetically healthy due to her age. Conversely, a 42-year-old with a high AMH may yield 16 eggs, yet the majority may carry severe chromosomal defects. AMH helps clinicians select the correct medication dosage; it is not a direct measure of whether a patient will conceive.

Truth 2: Injections cause systemic bloating and emotional swings rather than acute pain

Modern ovarian stimulation uses ultra-fine, short needles designed for subcutaneous delivery into abdominal fat. Most patients find the needle prick minor. The primary challenge stems from cumulative physiological and hormonal changes over the 10-to-14-day stimulation window.

As multiple follicles swell to 18-20 millimetres, the ovaries expand from the size of a walnut to the size of a plum or larger. This expansion exerts pressure on the bowel and bladder, producing pronounced abdominal distension, pelvic heaviness, and mild constipation. At the same time, serum oestrogen levels rise to ten or twenty times their normal physiological levels. This sudden surge frequently induces headaches, sudden fatigue, fluid retention, breast tenderness, and emotional volatility.

Truth 3: Egg retrieval is a minor surgical procedure managed with clinical sedation

Transvaginal oocyte collection is an operating-theatre procedure, but it is performed with effective analgesia. In UK clinics, patients typically receive deep conscious sedation using an intravenous combination of an opioid (such as fentanyl) and a sedative-hypnotic agent (such as propofol or midazolam), though some centres offer general anaesthesia.

Under sedation, the clinician inserts an ultrasound probe fitted with a needle guide into the vagina. A long, hollow needle punctures the vaginal wall, enters each ovary, and drains the follicular fluid under gentle suction pressure. While patients rarely feel sharp pain during the retrieval itself, post-operative sensation involves moderate uterine and ovarian cramping that peaks over the first 24 hours. Routine clinical management involves oral paracetamol, warm compresses, and non-steroidal anti-inflammatory drugs when approved by the treating clinician.

Truths 4 to 6: Embryo grading, cycle failure reasons, and single embryo transfer

Embryo grades reflect visual cell symmetry and development speed rather than genetic chromosomal normality, meaning even a top-graded blastocyst can fail to implant. Cycle failure is most frequently caused by invisible embryonic aneuploidy (abnormal chromosome counts) rather than uterine rejection or everyday patient activities. In line with UK regulatory safety standards, clinics recommend elective single embryo transfer (eSET) because multiple pregnancies carry significantly elevated maternal and neonatal risks.

Laboratory milestones and medical decision points often conflict with patient assumptions about embryo quality and transfer numbers.

Embryo Grade Component Assessment Focus Clinical Significance
Expansion Stage (1-6) Blastocoel cavity size and hatching status Indicates developmental tempo and readiness for transfer
Inner Cell Mass (A, B, C) Density and compaction of cells forming the fetus Higher grades (A/B) are associated with improved ongoing implantation
Trophectoderm (A, B, C) Cohesiveness of cells forming the placenta Crucial for uterine attachment and sustained hormonal support
Ploidy Status (Aneuploid/Euploid) Total chromosomal count (requires PGT-A) Visual grading cannot determine this critical genetic metric

Truth 4: Morphology grades are structural assessments, not genetic guarantees

UK embryology laboratories evaluate Day 5 blastocysts using standardised morphological scoring, most commonly the Gardner system. This system rates the degree of blastocoel expansion (numbers 1 to 6), the cell count and compaction of the inner cell mass (grades A, B, or C), and the cellular structure of the trophectoderm (grades A, B, or C).

A grade of "5AA" represents a visually textbook embryo: fully expanded with high cell numbers in both functional layers. However, morphological grading evaluates structural appearance under a microscope; it cannot detect sub-microscopic chromosomal deletions, duplications, or aneuploidies unless pre-implantation genetic testing for aneuploidies (PGT-A) is performed. An aesthetically normal 5AA blastocyst can be chromosomally abnormal (aneuploid) and fail to implant, while an irregular "3BC" blastocyst may be chromosomally normal (euploid) and result in a healthy live birth.

Truth 5: Implantation failure is usually biological, not behavioural

When a transferred embryo fails to establish a pregnancy, patients frequently wonder whether climbing stairs, returning to desk work, sneezing, or experiencing emotional stress caused the failure. Current reproductive medicine demonstrates that the vast majority of non-implantation events stem from embryonic arrest driven by fatal genetic or metabolic defects inside the blastocyst.

Successful implantation requires synchronised cross-talk between a genetically viable embryo and a receptive endometrium. If an embryo lacks the correct complement of 46 chromosomes, it will typically stop dividing within days of entering the uterine cavity. Uterine abnormalities (such as untreated polyps, thin endometrium, or chronic endometritis) account for a smaller proportion of implantation failures. Everyday physical movements, mild household tasks, and routine professional activities do not dislodge an embryo nestled into the endometrial lining.

Truth 6: Elective single embryo transfer prioritises maternal and infant safety

Patients self-funding expensive treatment often ask to transfer two or three embryos simultaneously, believing it doubles or triples their chances of conceiving. Modern UK fertility guidelines, established by the Human Fertilisation and Embryology Authority (HFEA), strongly discourage this practice, enforcing strict clinic-level caps on multiple births.

Elective single embryo transfer (eSET) offers comparable cumulative live birth rates while substantially reducing the clinical risks of a multiple pregnancy. Carrying twins substantially increases the risks of gestational diabetes, pre-eclampsia, emergency caesarean delivery, extreme preterm labour, low birth weight, and long-term neonatal neurological impairment. Transferring embryos one at a time across separate frozen cycles gives each blastocyst an independent, receptive uterine environment, preserving maternal health and reducing neonatal intensive care admissions.

Truths 7 and 8: The emotional strain and the realities of the two-week wait

The two-week wait (2WW) between embryo transfer and the official pregnancy test is widely reported as the most psychologically exhausting phase of treatment, compounded by progesterone side effects that mimic early pregnancy symptoms. The cumulative emotional burden of IVF often causes clinical distress, making planned psychological support, structured daily boundaries, and counselling essential throughout treatment.

Managing the physical and psychological changes during this period requires deliberate preparation.

Truth 7: Exogenous progesterone mimics early pregnancy sensations

Following an embryo transfer, patients take supplemental progesterone, delivered as vaginal pessaries, subcutaneous injections, or oral tablets, to support the luteal phase. Progesterone is the same hormone produced naturally by the corpus luteum and placenta during pregnancy.

Consequently, progesterone induces side effects identical to early pregnancy signs:

  • Pronounced breast tenderness and nipple sensitivity
  • Intermittent lower pelvic cramping and twinges
  • Persistent daytime somnolence and fatigue
  • Low-grade nausea and food aversions
  • Mild fluid retention and constipation

Patients often track every bodily sensation, assuming these signs prove successful implantation. Conversely, experiencing zero symptoms frequently triggers acute anxiety. In reality, these early physical changes are driven by pharmacological hormone supplementation. Furthermore, testing at home before the recommended test date often produces misleading results: residual hCG from a trigger injection can yield a false positive, while early testing before urinary hCG levels reach detectable thresholds causes false negatives.

Truth 8: Psychological fatigue accumulates across cycles and requires proactive support

Infertility is recognised clinically as a major life crisis, carrying levels of anxiety and depressive symptoms comparable to those seen in oncology and cardiology care. IVF introduces a continuous cycle of hope, procedural discomfort, diagnostic waiting, and acute grief if a cycle is unsuccessful. This emotional strain frequently spills into marriages, partnerships, and professional work, leading to social withdrawal and profound isolation.

Fertility professionals recommend establishing clear boundaries before starting treatment:

  • Limit daily internet and forum searching to a single 15-minute scheduled window.
  • Agree in advance on how and when to communicate cycle updates to family and friends.
  • Arrange professional fertility counselling through an accredited British Infertility Counselling Association (BICA) specialist, which UK-licensed centres routinely provide.
  • Establish a definitive plan for the pregnancy test day, including taking time off work and agreeing on how both partners will process the result together.

IVF success rates by age: what official UK data shows

According to official HFEA data, average UK live birth rates per embryo transfer are approximately 33% for patients under 35, 25% for ages 35 to 37, 17% for ages 38 to 39, 10% for ages 40 to 42, and below 5% for patients aged 43 and older using their own eggs. Maternal age remains the single most influential determinant of cycle outcome because of natural declines in oocyte quantity and chromosomal integrity.

When examining ivf success rates, patients must distinguish between positive pregnancy tests (biochemical pregnancies) and confirmed live births. A pregnancy test measures urinary or serum hCG, which indicates that an embryo has begun implantation. However, early pregnancy loss remains elevated when oocytes carry underlying chromosomal problems.

Official national statistics published by the Human Fertilisation and Embryology Authority demonstrate the real-world ivf success rates by age uk patients experience across domestic clinics:

Female Age at Treatment Live Birth Rate per Fresh Transfer Live Birth Rate per Frozen Transfer Approximate Risk of Miscarriage
Under 35 32%-35% 31%-34% 12%-15%
35-37 24%-26% 25%-28% 15%-20%
38-39 16%-18% 18%-21% 22%-28%
40-42 9%-11% 11%-13% 35%-42%
43-44 3%-5% 4%-6% 50%-55%
45 and older Below 2% Below 3% Above 60%

These figures reflect treatment using a patient's own genetic eggs. The steep decline observed after age 37 occurs because women are born with their lifetime supply of oocytes, which remain arrested in meiotic division until ovulation. Over time, the cellular machinery responsible for chromosome segregation becomes prone to errors, resulting in high rates of aneuploidy.

For patients over the age of 42, or those experiencing early ovarian insufficiency, clinics often recommend treatment with donor eggs. When a patient uses eggs retrieved from a healthy donor under the age of 35, the live birth rate per transfer immediately rises to roughly 30% to 35%, regardless of the recipient mother's age. This demonstrates that uterine receptivity remains largely preserved into a woman's late forties, confirming that oocyte age is the primary limiting factor in IVF success.

How much is IVF UK: private costs and NHS funding criteria

A single private round of IVF in the UK generally costs between £4,000 and £7,000 for standard clinic packages, with medication, blood tests, and embryo freezing routinely raising the total out-of-pocket spend to £6,000-£10,000 per cycle. NHS funding is commissioned regionally by Integrated Care Boards (ICBs) across England and devolved authorities, typically offering one to three funded cycles only to couples who meet strict age, BMI, non-smoking, and childlessness criteria.

Financial transparency is critical when planning fertility care. When evaluating how much UK IVF clinics charge, headline package figures rarely cover the full clinical journey.

Cost Component Typical Private UK Price Range Mandatory vs Optional Notes
Base Clinic IVF Package £3,500-£5,500 Mandatory Retrieval, routine lab culture, fresh transfer
Stimulation & Support Medications £1,200-£2,500 Mandatory Tailored to patient age and AMH level
Pre-treatment Screening £400-£800 Mandatory AMH, viral panels, pelvic ultrasound scans
ICSI (Intracytoplasmic Sperm Injection) £900-£1,400 Situational Used for male factor or previous low fertilisation
Embryo Freezing & 1 Year Storage £600-£1,200 Recommended Preserves surplus blastocysts for future use
Blastocyst Extended Culture £400-£700 Standard Culturing to Day 5 (often rolled into base fees)
HFEA Mandatory Patient Levy £85-£95 Mandatory Statutory regulatory fee paid per treatment cycle
PGT-A Genetic Screening £1,500-£2,500 Optional Biopsy and testing of a cohort of blastocysts

When patients calculate how much a round of IVF is in a private setting, a fully inclusive budget must sit between £7,000 and £10,000 to cover all necessary laboratory work and medication. If initial fresh transfers fail and frozen embryos remain in storage, a subsequent frozen embryo transfer (FET) costs an additional £1,500 to £2,500 per attempt.

NHS funding criteria and the regional postcode lottery

In the UK, public funding for fertility treatment is governed by guidance from the National Institute for Health and Care Excellence (NICE). NICE guidelines recommend that the NHS provide up to three full IVF cycles for women under 40 who have failed to conceive after two years of regular unprotected intercourse, and one cycle for eligible women aged 40 to 42.

However, the final funding decisions rest with local Integrated Care Boards (ICBs) in England, local Health Boards in Scotland and Wales, and Health and Social Care Trusts in Northern Ireland. This structure creates significant regional variation:

  • Female Age Limits: Most ICBs set an upper cutoff at 39 or 40, with some providing treatment only to women under 35.
  • Body Mass Index (BMI): Most NHS contracts strictly require the female partner to maintain a BMI between 19 and 30 kg/m² for at least six months before starting a cycle. Some regions also apply BMI restrictions to the male partner.
  • Smoking Status: Both partners must be verified non-smokers (often confirmed via carbon monoxide breath testing) for a minimum of three to six months.
  • Existing Children: Under "childless household" rules, if either partner has a living child from the current or any previous relationship, the couple is disqualified from receiving NHS funding across almost all English ICBs.
  • Number of Cycles: Scotland offers up to three funded IVF cycles for eligible patients, while many areas in England and Northern Ireland fund only one single fresh cycle.

Clinical risks and potential complications of IVF treatment

While modern IVF is generally safe, medical risks include ovarian hyperstimulation syndrome (OHSS), pelvic infection, intra-abdominal bleeding from retrieval, and ectopic pregnancy. Close ultrasound monitoring, modern antagonist stimulation protocols, and preventative agonist triggers have substantially reduced the incidence of severe OHSS in contemporary UK practice.

Assisted reproduction involves surgical interventions and hormone treatments, making it important to understand potential clinical complications and their typical frequencies:

  • Ovarian Hyperstimulation Syndrome (OHSS): This condition occurs when ovaries over-respond to stimulation medications, causing fluid to leak from vascular spaces into the peritoneal cavity, abdomen, and lungs. Mild OHSS (abdominal bloating, nausea) affects up to 20% to 30% of patients. Severe OHSS, marked by severe abdominal pain, persistent vomiting, pleural effusion, kidney dysfunction, and blood clots, develops in fewer than 1% to 2% of patients today. Clinics prevent severe OHSS by switching to GnRH antagonist protocols, using GnRH agonist triggers instead of hCG, and freezing all embryos for future transfer rather than performing a fresh transfer.
  • Surgical Complications During Retrieval: Puncturing the vaginal wall to reach the ovaries carries an approximate 1 in 1,000 risk of significant intra-abdominal bleeding or accidental injury to adjacent organs, such as the bladder, bowel, or major blood vessels. Pelvic infection occurs in fewer than 1 in 500 procedures, managed proactively with sterile surgical techniques and preventative antibiotics.
  • Ectopic and Heterotopic Pregnancy: Although embryos are placed directly into the uterine cavity, muscular contractions can occasionally push a blastocyst into the fallopian tube. Ectopic pregnancy occurs in roughly 1% to 3% of all IVF clinical pregnancies. If an embryo implants concurrently in the uterus and a fallopian tube (heterotopic pregnancy), prompt laparoscopic surgical intervention is required to protect the intrauterine pregnancy where possible.
  • Multiple Pregnancy Risks: If clinics transfer more than one embryo, the risk of carrying twins or triplets rises to roughly 20% per transfer. Multiple pregnancies carry a four-fold increase in the rate of infant cerebral palsy, a six-fold increase in neonatal mortality, and substantially higher rates of maternal pre-eclampsia and postpartum haemorrhage.

Patients should contact their fertility clinic immediately, or seek local emergency hospital care, if they develop severe lower abdominal pain, rapid abdominal enlargement, shortness of breath, continuous dizziness, heavy vaginal bleeding soaking more than two sanitary pads an hour, or a fever above 38°C after egg retrieval.

Frequently Asked Questions

Answers to practical questions regarding private cycle budgeting, NHS criteria differences, and procedure preparation.

How much is IVF UK NHS care, and who qualifies?

NHS-funded IVF treatment is free at the point of care for eligible patients, covering medical consultations, stimulation drugs, egg retrieval, laboratory fertilisation, and the transfer of approved embryos. However, regional ICBs cap the number of funded cycles, often to just one round, and patients must cover secondary costs if they exceed local limits, such as private embryo storage fees after their contracted NHS storage term ends.

What is IVF treatment and who needs it?

In vitro fertilisation is an assisted reproductive procedure used when natural conception is prevented by physical blockages, reduced gamete numbers, or unexplained cellular issues. It is commonly recommended for individuals with blocked or damaged fallopian tubes, severe male-factor subfertility, advanced stage endometriosis, age-related fertility decline, or those needing pre-implantation genetic testing to avoid passing on serious inherited conditions.

How many IVF cycles are typically needed to achieve a baby?

Most patients require two to three complete IVF cycles to achieve a confirmed live birth. Because the live birth rate per single transfer for women under 35 averages around 33%, cumulative success builds as multiple fresh and frozen blastocysts are transferred across sequential treatment cycles.

Can pre-implantation genetic testing (PGT-A) guarantee a live birth?

PGT-A screens an embryo's cells for chromosomal balance, identifying euploid blastocysts and lowering the clinical risk of early miscarriage. However, transferring a genetically normal embryo cannot guarantee a live birth, as successful implantation also depends on endometrial health, uterine anatomy, and underlying vascular conditions.

Not sure which hospital is right for your case?

Upload your medical reports and our AI will match them against the verified capabilities of every hospital in our network.

  1. Upload your reports (no account needed)
  2. Our AI matches your case with hospitals that can actually treat it
  3. You choose who receives your case. We present it in the hospital's own language, and the hospital replies directly to you

Free and anonymous. Your documents stay private until you decide to send them.

Upload your reports

More from the blog